The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://marcmlrf775721.blog-eye.com/42149068/retatrutide-and-nmn-a-combined-approach-to-general-condition